Loading
Monoclonal antibodies and ADCs have moved from weight-based to flat dosing on modelling alone, which is convenient but gives lighter patients relatively more drug. Randomised or pharmacokinetic comparisons, plus rounding doses to vial sizes where exposure is equivalent, could keep effectiveness while cutting cost and waste.
Randomised or PK-bridging comparisons of flat versus weight-based (or weight-banded) dosing for monoclonal antibodies and ADCs where flat dosing was adopted on modelling alone; pharmacy dose-banding and vial sharing implemented as policy where exposure equivalence is shown. Payers fund the trials; savings are large because these agents dominate oncology drug spend.
Shares Wrong doses, Prices and value.
Shares Interstitial lung disease (ILD) / pneumonitis, Wrong doses, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Wrong doses, Prices and value, Pembrolizumab.
Shares Trastuzumab deruxtecan, Monoclonal antibodies, Antibody-drug conjugate (ADC), Pembrolizumab.
Shares Wrong doses, Prices and value, Pembrolizumab.
Shares Interstitial lung disease (ILD) / pneumonitis, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Prices and value, Monoclonal antibodies, Pembrolizumab.
Shares Wrong doses, Monoclonal antibodies, Antibody-drug conjugate (ADC).